Le Lézard
Classified in: Health
Subjects: NPT, CHI, BFA

Niagara Falls 'Miracle' Baby Beats Aggressive Leukemia After Successful CAR-T Cancer Immunotherapy at Roswell Park Oishei Children's Cancer and Blood Disorders Program


BUFFALO, N.Y., Oct. 1, 2020 /PRNewswire/ -- "She's a bundle of joy, she's a blessing. She's just life." That's what Cariorl Mayfield of Niagara Falls, NY, says about his daughter, Chastity, who was treated at the Roswell Park Oishei Children's Cancer and Blood Disorders Program for the leukemia she was diagnosed with at 5 weeks old.

Today, Chastity no signs of cancer after undergoing CAR T therapy, short for chimeric antigen receptor T-cell therapy ? and is one of the youngest patients to receive this advanced cancer treatment. She received a form of CAR T called Kymriah, also known as tisagenlecleucel, which Roswell Park Comprehensive Cancer Center has been a certified treatment center for since 2018.

Chastity's battle with leukemia began in fall 2018. Childhood cancer expert Kara Kelly, MD, from the Roswell Park Oishei Children's Cancer and Blood Disorders Program would diagnose Chastity with an aggressive, treatment-resistant blood cancer, acute lymphocytic leukemia (ALL).

Chastity faced even greater odds as a Black infant with aggressive leukemia. A 2018 study reported that a Black child with ALL is 43 percent more likely to die than a white child with the same diagnosis.

The team believes Chastity, 7 months old at the time, may be the youngest patient to successfully complete CAR T therapy followed by blood and marrow transplant, or BMT, with long-term remission from cancer.

As she nears her 2nd birthday, Chastity is walking, talking and showing no evidence at all of the leukemia that once wracked her body.

"I look at her as our little miracle," says Dr. Higman.

Learn more about Chastity's journey at https://www.roswellpark.org/newsroom/202010-niagara-falls-miracle-baby-beats-aggressive-leukemia-after-successful-car-t-cancer

About the Roswell Park Oishei Children's Cancer and Blood Disorders Program

The Roswell Park Oishei Children's Cancer and Blood Disorders Program cares for children using advanced medical technology, with multidisciplinary care that is focused on the needs of the families we serve. We seamlessly operate one of few programs nationally to offer pediatric patients the resources of both a National Cancer Institute-designated Comprehensive Cancer Center and a freestanding children's hospital, with outpatient care provided at Roswell Park Comprehensive Cancer Center and inpatient care at Oishei Children's Hospital. Our research makes a difference in the lives of children treated in our community, nationally and worldwide. To learn more about the Roswell Park Oishei Children's Cancer and Blood Disorders Program, call 1-800-ROSWELL (1-800-767-9355).

 

SOURCE Roswell Park Comprehensive Cancer Center


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: